Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT).

Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y.

Clin Cancer Res. 2019 Jun 4. pii: clincanres.0103.2019. doi: 10.1158/1078-0432.CCR-19-0103. [Epub ahead of print]

PMID:
31164373
2.

Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.

Kunimasa K, Nakamura H, Sakai K, Tamiya M, Kimura M, Inoue T, Nishino K, Kuhara H, Nakatsuka SI, Nishio K, Imamura F, Kumagai T.

Lung Cancer. 2019 Jun;132:59-64. doi: 10.1016/j.lungcan.2019.03.029. Epub 2019 Apr 8.

PMID:
31097095
3.

Driving status, travel modes and accelerometer-assessed physical activity in younger, middle-aged and older adults: a prospective study of 90 810 UK Biobank participants.

Hajna S, White T, Panter J, Brage S, Wijndaele K, Woodcock J, Ogilvie D, Imamura F, Griffin SJ.

Int J Epidemiol. 2019 Apr 19. pii: dyz065. doi: 10.1093/ije/dyz065. [Epub ahead of print]

PMID:
31004155
4.

Changes in plasma phospholipid fatty acid profiles over 13 years and correlates of change: European Prospective Investigation into Cancer and Nutrition-Norfolk Study.

Zheng JS, Imamura F, Sharp SJ, Koulman A, Griffin JL, Mulligan AA, Luben R, Khaw KT, Wareham NJ, Forouhi NG.

Am J Clin Nutr. 2019 Jun 1;109(6):1527-1534. doi: 10.1093/ajcn/nqz030.

5.

Associations of circulating very-long-chain saturated fatty acids and incident type 2 diabetes: a pooled analysis of prospective cohort studies.

Fretts AM, Imamura F, Marklund M, Micha R, Wu JHY, Murphy RA, Chien KL, McKnight B, Tintle N, Forouhi NG, Qureshi WT, Virtanen JK, Wong K, Wood AC, Lankinen M, Rajaobelina K, Harris TB, Djoussé L, Harris B, Wareham NJ, Steffen LM, Laakso M, Veenstra J, Samieri C, Brouwer IA, Yu CI, Koulman A, Steffen BT, Helmer C, Sotoodehnia N, Siscovick D, Gudnason V; InterAct Consortium, Wagenknecht L, Voutilainen S, Tsai MY, Uusitupa M, Kalsbeek A, Berr C, Mozaffarian D, Lemaitre RN.

Am J Clin Nutr. 2019 Apr 1;109(4):1216-1223. doi: 10.1093/ajcn/nqz005.

PMID:
30982858
6.

Biomarkers of Dietary Omega-6 Fatty Acids and Incident Cardiovascular Disease and Mortality.

Marklund M, Wu JHY, Imamura F, Del Gobbo LC, Fretts A, de Goede J, Shi P, Tintle N, Wennberg M, Aslibekyan S, Chen TA, de Oliveira Otto MC, Hirakawa Y, Eriksen HH, Kröger J, Laguzzi F, Lankinen M, Murphy RA, Prem K, Samieri C, Virtanen J, Wood AC, Wong K, Yang WS, Zhou X, Baylin A, Boer JMA, Brouwer IA, Campos H, Chaves PHM, Chien KL, de Faire U, Djoussé L, Eiriksdottir G, El-Abbadi N, Forouhi NG, Michael Gaziano J, Geleijnse JM, Gigante B, Giles G, Guallar E, Gudnason V, Harris T, Harris WS, Helmer C, Hellenius ML, Hodge A, Hu FB, Jacques PF, Jansson JH, Kalsbeek A, Khaw KT, Koh WP, Laakso M, Leander K, Lin HJ, Lind L, Luben R, Luo J, McKnight B, Mursu J, Ninomiya T, Overvad K, Psaty BM, Rimm E, Schulze MB, Siscovick D, Skjelbo Nielsen M, Smith AV, Steffen BT, Steffen L, Sun Q, Sundström J, Tsai MY, Tunstall-Pedoe H, Uusitupa MIJ, van Dam RM, Veenstra J, Monique Verschuren WM, Wareham N, Willett W, Woodward M, Yuan JM, Micha R, Lemaitre RN, Mozaffarian D, Risérus U; Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Fatty Acids and Outcomes Research Consortium (FORCE).

Circulation. 2019 May 21;139(21):2422-2436. doi: 10.1161/CIRCULATIONAHA.118.038908.

PMID:
30971107
7.

Regional differences in mitral cell development in mouse olfactory bulb.

Nguyen UP, Imamura F.

J Comp Neurol. 2019 Mar 13. doi: 10.1002/cne.24683. [Epub ahead of print]

PMID:
30864157
8.

Assessing the causal association of glycine with risk of cardio-metabolic diseases.

Wittemans LBL, Lotta LA, Oliver-Williams C, Stewart ID, Surendran P, Karthikeyan S, Day FR, Koulman A, Imamura F, Zeng L, Erdmann J, Schunkert H, Khaw KT, Griffin JL, Forouhi NG, Scott RA, Wood AM, Burgess S, Howson JMM, Danesh J, Wareham NJ, Butterworth AS, Langenberg C.

Nat Commun. 2019 Mar 5;10(1):1060. doi: 10.1038/s41467-019-08936-1.

9.

Narrowly Confined and Glomerulus-Specific Onset Latencies of Odor-Evoked Calcium Transients in the Juxtaglomerular Cells of the Mouse Main Olfactory Bulb.

Homma R, Lv X, Sato T, Imamura F, Zeng S, Nagayama S.

eNeuro. 2019 Feb 28;6(1). pii: ENEURO.0387-18.2019. doi: 10.1523/ENEURO.0387-18.2019. eCollection 2019 Jan-Feb.

10.

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.

Sugawara S, Nakagawa K, Yamamoto N, Nokihara H, Ohe Y, Nishio M, Takahashi T, Goto K, Maemondo M, Ichinose Y, Seto T, Sakai H, Gemma A, Imamura F, Shingyoji M, Saka H, Inoue A, Takeda K, Okamoto I, Kiura K, Morita S, Tamura T.

Int J Clin Oncol. 2019 May;24(5):485-493. doi: 10.1007/s10147-019-01396-z. Epub 2019 Mar 4.

11.

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.

Nishio M, Murakami H, Ohe Y, Hida T, Sakai H, Kasahara K, Imamura F, Baba T, Kubota K, Hosomi Y, Shimokawa T, Hayashi H, Miyadera K, Tamura T.

Invest New Drugs. 2019 Feb 21. doi: 10.1007/s10637-019-00732-4. [Epub ahead of print]

PMID:
30790152
12.

Dairy Product Intake and Risk of Type 2 Diabetes in EPIC-InterAct: A Mendelian Randomization Study.

Vissers LET, Sluijs I, van der Schouw YT, Forouhi NG, Imamura F, Burgess S, Barricarte A, Boeing H, Bonet C, Chirlaque MD, Fagherazzi G, Franks PW, Freisling H, Gunter MJ, Quirós JR, Ibsen DB, Kaaks R, Key T, Khaw KT, Kühn T, Mokoroa O, Nilsson PM, Overvad K, Pala V, Palli D, Panico S, Sacerdote C, Spijkerman AMW, Tjonneland A, Tumino R, Rodríguez-Barranco M, Rolandsson O, Riboli E, Sharp SJ, Langenberg C, Wareham NJ.

Diabetes Care. 2019 Apr;42(4):568-575. doi: 10.2337/dc18-2034. Epub 2019 Feb 6.

13.

The obesity transition: stages of the global epidemic.

Jaacks LM, Vandevijvere S, Pan A, McGowan CJ, Wallace C, Imamura F, Mozaffarian D, Swinburn B, Ezzati M.

Lancet Diabetes Endocrinol. 2019 Mar;7(3):231-240. doi: 10.1016/S2213-8587(19)30026-9. Epub 2019 Jan 28. Review.

PMID:
30704950
14.

The association between adherence to the Mediterranean diet and hepatic steatosis: cross-sectional analysis of two independent studies, the UK Fenland Study and the Swiss CoLaus Study.

Khalatbari-Soltani S, Imamura F, Brage S, De Lucia Rolfe E, Griffin SJ, Wareham NJ, Marques-Vidal P, Forouhi NG.

BMC Med. 2019 Jan 24;17(1):19. doi: 10.1186/s12916-019-1251-7.

15.

Predictors of Acute Radiation Esophagitis in Non-small Cell Lung Cancer Patients Treated With Accelerated Hyperfractionated Chemoradiotherapy.

Wada K, Kishi N, Kanayama N, Hirata T, Ueda Y, Kawaguchi Y, Morimoto M, Konishi K, Imamura F, Ogawa K, Teshima T.

Anticancer Res. 2019 Jan;39(1):491-497. doi: 10.21873/anticanres.13139.

PMID:
30591500
16.

A Meta-Analysis of Food Labeling Effects on Consumer Diet Behaviors and Industry Practices.

Shangguan S, Afshin A, Shulkin M, Ma W, Marsden D, Smith J, Saheb-Kashaf M, Shi P, Micha R, Imamura F, Mozaffarian D; Food PRICE (Policy Review and Intervention Cost-Effectiveness) Project.

Am J Prev Med. 2019 Feb;56(2):300-314. doi: 10.1016/j.amepre.2018.09.024. Epub 2018 Dec 17. Review.

PMID:
30573335
17.

Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.

Kinehara Y, Nagatomo I, Koyama S, Ito D, Nojima S, Kurebayashi R, Nakanishi Y, Suga Y, Nishijima-Futami Y, Osa A, Nakatani T, Kato Y, Nishide M, Hayama Y, Higashiguchi M, Morimura O, Miyake K, Kang S, Minami T, Hirata H, Iwahori K, Takimoto T, Takamatsu H, Takeda Y, Hosen N, Hoshino S, Shintani Y, Okumura M, Kumagai T, Nishino K, Imamura F, Nakatsuka SI, Kijima T, Kida H, Kumanogoh A.

JCI Insight. 2018 Dec 20;3(24). pii: 123093. doi: 10.1172/jci.insight.123093.

18.

D1 dopamine receptors intrinsic activity and functional selectivity affect working memory in prefrontal cortex.

Yang Y, Lee SM, Imamura F, Gowda K, Amin S, Mailman RB.

Mol Psychiatry. 2018 Dec 7. doi: 10.1038/s41380-018-0312-1. [Epub ahead of print]

PMID:
30532019
19.

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset.

Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K.

Jpn J Clin Oncol. 2019 Jan 1;49(1):29-36. doi: 10.1093/jjco/hyy179.

20.

First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.

Kishi K, Sakai H, Seto T, Kozuki T, Nishio M, Imamura F, Nokihara H, Satouchi M, Nakagawa S, Tahata T, Nakagawa K.

Cancer Treat Res Commun. 2019;18:100113. doi: 10.1016/j.ctarc.2018.10.004. Epub 2018 Oct 31.

21.

Association of Plasma Vitamin D Metabolites With Incident Type 2 Diabetes: EPIC-InterAct Case-Cohort Study.

Zheng JS, Imamura F, Sharp SJ, van der Schouw YT, Sluijs I, Gundersen TE, Ardanaz E, Boeing H, Bonet C, Gómez JH, Dow C, Fagherazzi G, Franks PW, Jenab M, Kühn T, Kaaks R, Key TJ, Khaw KT, Lasheras C, Mokoroa O, Mancini FR, Nilsson PM, Overvad K, Panico S, Palli D, Rolandsson O, Sieri S, Salamanca-Fernández E, Sacerdote C, Spijkerman AMW, Stepien M, Tjonneland A, Tumino R, Butterworth AS, Riboli E, Danesh J, Langenberg C, Forouhi NG, Wareham NJ.

J Clin Endocrinol Metab. 2019 Apr 1;104(4):1293-1303. doi: 10.1210/jc.2018-01522.

22.

Circulating Phylloquinone Concentrations and Risk of Type 2 Diabetes: A Mendelian Randomization Study.

Zwakenberg SR, Remmelzwaal S, Beulens JWJ, Booth SL, Burgess S, Dashti HS, Imamura F, Feskens EJM, van der Schouw YT, Sluijs I.

Diabetes. 2019 Jan;68(1):220-225. doi: 10.2337/db18-0543. Epub 2018 Oct 23.

23.

Aldehyde dehydrogenase 2 genotype in tolerability of alcohol contained in paclitaxel in Japanese breast cancer patients.

Yagi T, Fujiishi K, Hasegawa A, Otsuka T, Yoshinami T, Nishio M, Fujisawa F, Sugimoto N, Imamura F.

Breast Cancer. 2019 Mar;26(2):229-234. doi: 10.1007/s12282-018-0918-9. Epub 2018 Oct 22.

PMID:
30350259
24.

High-throughput screening in colorectal cancer tissue-originated spheroids.

Kondo J, Ekawa T, Endo H, Yamazaki K, Tanaka N, Kukita Y, Okuyama H, Okami J, Imamura F, Ohue M, Kato K, Nomura T, Kohara A, Mori S, Dan S, Inoue M.

Cancer Sci. 2019 Jan;110(1):345-355. doi: 10.1111/cas.13843. Epub 2018 Nov 20.

25.

Neuroplastic changes in the olfactory bulb associated with nasal inflammation in mice.

Hasegawa-Ishii S, Shimada A, Imamura F.

J Allergy Clin Immunol. 2019 Mar;143(3):978-989.e3. doi: 10.1016/j.jaci.2018.09.028. Epub 2018 Oct 10.

PMID:
30315829
26.

Fatty acid biomarkers of dairy fat consumption and incidence of type 2 diabetes: A pooled analysis of prospective cohort studies.

Imamura F, Fretts A, Marklund M, Ardisson Korat AV, Yang WS, Lankinen M, Qureshi W, Helmer C, Chen TA, Wong K, Bassett JK, Murphy R, Tintle N, Yu CI, Brouwer IA, Chien KL, Frazier-Wood AC, Del Gobbo LC, Djoussé L, Geleijnse JM, Giles GG, de Goede J, Gudnason V, Harris WS, Hodge A, Hu F; InterAct Consortium, Koulman A, Laakso M, Lind L, Lin HJ, McKnight B, Rajaobelina K, Risérus U, Robinson JG, Samieri C, Siscovick DS, Soedamah-Muthu SS, Sotoodehnia N, Sun Q, Tsai MY, Uusitupa M, Wagenknecht LE, Wareham NJ, Wu JH, Micha R, Forouhi NG, Lemaitre RN, Mozaffarian D; Fatty Acids and Outcomes Research Consortium (FORCE).

PLoS Med. 2018 Oct 10;15(10):e1002670. doi: 10.1371/journal.pmed.1002670. eCollection 2018 Oct.

27.

Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer.

Wada K, Kishi N, Kanayama N, Hirata T, Morimoto M, Konishi K, Imamura F, Teshima T, Ogawa K.

Anticancer Res. 2018 Oct;38(10):5951-5958. doi: 10.21873/anticanres.12941.

PMID:
30275224
28.

Genome-wide association study for risk taking propensity indicates shared pathways with body mass index.

Clifton EAD, Perry JRB, Imamura F, Lotta LA, Brage S, Forouhi NG, Griffin SJ, Wareham NJ, Ong KK, Day FR.

Commun Biol. 2018 May 3;1:36. doi: 10.1038/s42003-018-0042-6. eCollection 2018.

29.

Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.

Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S.

Lung Cancer. 2018 Oct;124:65-70. doi: 10.1016/j.lungcan.2018.07.031. Epub 2018 Jul 23.

PMID:
30268482
30.

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.

Cho BC, Chewaskulyong B, Lee KH, Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cheng Y, Cho EK, Voon PJ, Lee JS, Mann H, Saggese M, Reungwetwattana T, Ramalingam SS, Ohe Y.

J Thorac Oncol. 2019 Jan;14(1):99-106. doi: 10.1016/j.jtho.2018.09.004. Epub 2018 Sep 18.

PMID:
30240852
31.

Assessing dietary intakes from household budget surveys: A national analysis in Bangladesh.

Karageorgou D, Imamura F, Zhang J, Shi P, Mozaffarian D, Micha R.

PLoS One. 2018 Aug 27;13(8):e0202831. doi: 10.1371/journal.pone.0202831. eCollection 2018.

32.

Heterogeneity of EGFR-mutant clones and PD-L1 highly expressing clones affects treatment efficacy of EGFR-TKI and PD-1 inhibitor.

Kunimasa K, Nakamura H, Sakai K, Kimura M, Inoue T, Tamiya M, Nishino K, Kumagai T, Nakatsuka S, Endo H, Inoue M, Nishio K, Imamura F.

Ann Oncol. 2018 Oct 1;29(10):2145-2147. doi: 10.1093/annonc/mdy312. No abstract available.

PMID:
30099497
33.

Nivolumab induced vitiligo-like lesions in a patient with metastatic squamous cell carcinoma of the lung.

Nishino K, Ohe S, Kitamura M, Kunimasa K, Kimura M, Inoue T, Tamiya M, Kumagai T, Nakatsuka SI, Isei T, Imamura F.

J Thorac Dis. 2018 Jun;10(6):E481-E484. doi: 10.21037/jtd.2018.05.104. No abstract available.

34.

Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer.

Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa SI, Inoue T, Imamura F, Atagi S, Hirashima T.

Anticancer Res. 2018 Aug;38(8):4723-4729. doi: 10.21873/anticanres.12779.

PMID:
30061241
35.

Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.

Shibuya H, Hijioka S, Sakamoto Y, Ito T, Ueda K, Komoto I, Kobayashi N, Kudo A, Yasuda H, Miyake H, Arita J, Kiritani S, Ikeda M, Imaoka H, Ueno M, Kobayashi S, Furuta M, Nagashio Y, Murohisa G, Aoki T, Matsumoto S, Motoya M, Azemoto N, Itakura J, Horiguchi S, Yogi T, Kawagoe T, Miyaoka Y, Imamura F, Senju M, Arioka H, Hara K, Imamura M, Okusaka T.

Cancer Chemother Pharmacol. 2018 Oct;82(4):661-668. doi: 10.1007/s00280-018-3656-y. Epub 2018 Jul 27.

PMID:
30054710
36.

Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction.

Kunimasa K, Isei T, Nakamura H, Kimura M, Inoue T, Tamiya M, Nishino K, Kumagai T, Nakatsuka SI, Endo H, Inoue M, Imamura F.

Invest New Drugs. 2018 Dec;36(6):1138-1142. doi: 10.1007/s10637-018-0628-3. Epub 2018 Jun 26.

PMID:
29947012
37.

Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab.

Nakahama K, Tamiya A, Isa SI, Taniguchi Y, Shiroyama T, Suzuki H, Inoue T, Tamiya M, Hirashima T, Imamura F, Atagi S.

In Vivo. 2018 Jul-Aug;32(4):887-891. doi: 10.21873/invivo.11324.

38.

Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption.

Sanders FWB, Acharjee A, Walker C, Marney L, Roberts LD, Imamura F, Jenkins B, Case J, Ray S, Virtue S, Vidal-Puig A, Kuh D, Hardy R, Allison M, Forouhi N, Murray AJ, Wareham N, Vacca M, Koulman A, Griffin JL.

Genome Biol. 2018 Jun 20;19(1):79. doi: 10.1186/s13059-018-1439-8.

39.

Pembrolizumab-induced acute thrombosis: A case report.

Kunimasa K, Nishino K, Kimura M, Inoue T, Tamiya M, Kumagai T, Imamura F.

Medicine (Baltimore). 2018 May;97(20):e10772. doi: 10.1097/MD.0000000000010772.

40.

Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.

Akamatsu H, Katakami N, Okamoto I, Kato T, Kim YH, Imamura F, Shinkai M, Hodge RA, Uchida H, Hida T.

Cancer Sci. 2018 Jun;109(6):1930-1938. doi: 10.1111/cas.13623. Epub 2018 May 31.

41.

Dietary cost associated with adherence to the Mediterranean diet, and its variation by socio-economic factors in the UK Fenland Study.

Tong TYN, Imamura F, Monsivais P, Brage S, Griffin SJ, Wareham NJ, Forouhi NG.

Br J Nutr. 2018 Mar;119(6):685-694. doi: 10.1017/S0007114517003993.

42.

Interplay between genetic predisposition, macronutrient intake and type 2 diabetes incidence: analysis within EPIC-InterAct across eight European countries.

Li SX, Imamura F, Schulze MB, Zheng J, Ye Z, Agudo A, Ardanaz E, Aune D, Boeing H, Dorronsoro M, Dow C, Fagherazzi G, Grioni S, Gunter MJ, Huerta JM, Ibsen DB, Jakobsen MU, Kaaks R, Key TJ, Khaw KT, Kyrø C, Mancini FR, Molina-Portillo E, Murphy N, Nilsson PM, Onland-Moret NC, Palli D, Panico S, Poveda A, Quirós JR, Ricceri F, Sluijs I, Spijkerman AMW, Tjonneland A, Tumino R, Winkvist A, Langenberg C, Sharp SJ, Riboli E, Scott RA, Forouhi NG, Wareham NJ.

Diabetologia. 2018 Jun;61(6):1325-1332. doi: 10.1007/s00125-018-4586-2. Epub 2018 Mar 17.

43.

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.

Okamoto I, Morita S, Tashiro N, Imamura F, Inoue A, Seto T, Yamamoto N, Ohe Y, Nakagawa K, Fukuoka M.

Lung Cancer. 2018 Mar;117:14-19. doi: 10.1016/j.lungcan.2018.01.005. Epub 2018 Jan 9.

44.

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.

Kiura K, Imamura F, Kagamu H, Matsumoto S, Hida T, Nakagawa K, Satouchi M, Okamoto I, Takenoyama M, Fujisaka Y, Kurata T, Ito M, Tokushige K, Hatano B, Nishio M.

Jpn J Clin Oncol. 2018 Apr 1;48(4):367-375. doi: 10.1093/jjco/hyy016.

45.

HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1.

Kumagai T, Tomita Y, Nakatsuka SI, Kimura M, Kunimasa K, Inoue T, Tamiya M, Nishino K, Susaki Y, Kusu T, Tokunaga T, Okami J, Higashiyama M, Imamura F.

Thorac Cancer. 2018 Apr;9(4):466-471. doi: 10.1111/1759-7714.12609. Epub 2018 Feb 23.

46.

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial.

Tamiya M, Tamiya A, Inoue T, Kimura M, Kunimasa K, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Nishino K, Kumagai T, Suzuki H, Hirashima T, Atagi S, Imamura F.

PLoS One. 2018 Feb 22;13(2):e0192227. doi: 10.1371/journal.pone.0192227. eCollection 2018.

47.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators.

N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.

48.

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.

Shiroyama T, Suzuki H, Tamiya M, Tamiya A, Tanaka A, Okamoto N, Nakahama K, Taniguchi Y, Isa SI, Inoue T, Imamura F, Atagi S, Hirashima T.

Cancer Med. 2018 Jan;7(1):13-20. doi: 10.1002/cam4.1234. Epub 2017 Nov 18.

49.

Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries: a cross-sectional analysis in the EPIC-InterAct study.

Zheng JS, Sharp SJ, Imamura F, Koulman A, Schulze MB, Ye Z, Griffin J, Guevara M, Huerta JM, Kröger J, Sluijs I, Agudo A, Barricarte A, Boeing H, Colorado-Yohar S, Dow C, Dorronsoro M, Dinesen PT, Fagherazzi G, Franks PW, Feskens EJM, Kühn T, Katzke VA, Key TJ, Khaw KT, de Magistris MS, Mancini FR, Molina-Portillo E, Nilsson PM, Olsen A, Overvad K, Palli D, Quirós JR, Rolandsson O, Ricceri F, Spijkerman AMW, Slimani N, Tagliabue G, Tjonneland A, Tumino R, van der Schouw YT, Langenberg C, Riboli E, Forouhi NG, Wareham NJ.

BMC Med. 2017 Nov 17;15(1):203. doi: 10.1186/s12916-017-0968-4.

50.

Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab.

Inoue T, Tamiya M, Tamiya A, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Nishino K, Kumagai T, Kunimasa K, Kimura M, Suzuki H, Hirashima T, Atagi S, Imamura F.

Clin Lung Cancer. 2018 Mar;19(2):e171-e176. doi: 10.1016/j.cllc.2017.09.002. Epub 2017 Oct 13.

PMID:
29133121

Supplemental Content

Loading ...
Support Center